The opening of the IPO window in the past six months has provided companies with more alternatives than they’ve had. Firms have relied on angel investors for seed capital. But, when the IPO window closed a few years ago, companies were stranded, relying mainly on acquisitions and big pharma deals to reach the next level. Now, “rather than negotiate from weakness with big pharma, companies can go to public markets as a proactive alternative.” Read more »
One of San Diego Tech Coast Angels’ hallmarks is its willingness to look at companies very early in their development—often when they are at the “two guys and a patentable idea” stage. Although that is too early for the usual development fund, it is right for a relatively new option called the Seed Track. Read more »
EntreMed leverages the best aspects of China and the United States to advance its mission of developing oncology therapeutics. With headquarters in Maryland and a wholly-owned subsidiary and R&D center in Beijing, it brings its Western partners the significant advantage of advancing drug development with improved efficiency, cost-effectiveness and faster access to the world’s fastest growing pharmaceutical market. Read more »
TheraKine Ltd. has developed an innovative drug delivery technology that enables biologics, small molecules, proteins and peptides to be delivered in a sustained release format without any chemical or biologic modifications. The company works with others to repurpose drugs in a way that enables them to be used more safely and more effectively. Read more »
Returning to Vienna marked an all-time record for Europe’s largest meeting for business development in life sciences. Read more »
It was standing room only for a BIO-Europe® panel discussion by four pharma licensing executives for some advice on how best to successfully position a drug development program for licensing, how to prepare the asset for dealmaking, how to make a program visible to buyers, what to say about it, and equally important, what not to say. Read more »
Patients have something to say about drug development, according to Tony Coles, former CEO for Onyx Pharmaceuticals.
Listening to patients earned Onyx USD 125 per share in cash from Amgen, the fifth largest biotechnology deal in history with a valuation of USD 10.4 billion. Read more »
In his role as vice chair for the European Technology Platform on Nanomedicine, Laurent Levy described the state of the emerging field of nano-therapeutics to set the context for a special workshop at BIO-Europe® 2013 asking, ” Is nano becoming the next sweet spot for drug development?” Read more »
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.
Sign up today to the free newsletter and never miss any new content.